Letter: a 5‐year long‐term follow‐up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis.
Saved in:
| Title: | Letter: a 5‐year long‐term follow‐up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis. |
|---|---|
| Authors: | Ebel, Friederike1 (AUTHOR), Deterding, Katja2 (AUTHOR), Port, Kerstin1 (AUTHOR), Schlevogt, Bernhard3 (AUTHOR), Manns, Michael P.1,4,5 (AUTHOR), Maasoumy, Benjamin1 (AUTHOR), Cornberg, Markus1 (AUTHOR), Wedemeyer, Heiner2,4,5 (AUTHOR) Wedemeyer.Heiner@mh-hannover.de |
| Source: | Alimentary Pharmacology & Therapeutics. Jan2020, Vol. 51 Issue 1, p194-195. 2p. 1 Graph. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
